Leqembi

News

Appeal finds NICE must reconsider Alzheimer's drugs

Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.

News

Leqembi starts to deliver for Eisai and Biogen

Three years after its first launch in the US, there are signs that Biogen and Eisai's Alzheimer's Leqembi therapy is gathering sales momentum.

News

Eisai moves swiftly to expand subcutaneous Leqembi label

Before it has even launched, Eisai has filed to widen subcutaneous Leqembi's label to include starting as well as maintenance dosing in Alzheimer's.

News

Dose-at-home Leqembi for Alzheimer's cleared in US

Eisai and Biogen get FDA approval for subcutaneous Leqembi. Will it help stave off growing competition from Lilly's Kisunla in Alzheimer's treatment?

News

Alzheimer's drug Leqembi launched in first EU markets

Germany and Austria are the first countries in the EU to see the launch of Leqembi, Eisai and Biogen's much-delayed treatment for Alzheimer's.

News

Dismay but little surprise as NICE rejects Alzheimer's drugs

Eli Lilly and Eisai's hopes of making their Alzheimer's disease therapies available to NHS patients in England have been knocked back once again.

Appeal finds NICE must reconsider Alzheimer's drugs

Leqembi starts to deliver for Eisai and Biogen

Eisai moves swiftly to expand subcutaneous Leqembi label

Dose-at-home Leqembi for Alzheimer's cleared in US

Alzheimer's drug Leqembi launched in first EU markets

Dismay but little surprise as NICE rejects Alzheimer's drugs

Hernexeos and what’s next, with Vicky Brown

Using AI-driven synthetic personas to take your insights fur...

Leqembi

Editor's Picks